Clinical trials

Safety Profile of Psilocybin for Cocaine Use Disorder (opens ClinicalTrials.gov in a new tab)

Suspended • Early Phase 1 • 10 participants • University of California, Los Angeles

Cocaine Use Disorder

Comparative Effects of Four Brief Breathwork and Mindfulness Interventions on Anxiety and Psychological Flexibility: A 4-Arm RCT (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • 240 participants • Valencian International University (VIU)

Anxiety, Psychological Flexibility, Stress

NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • Phase 2 • 83 participants • M.D. Anderson Cancer Center

Psilocybin, Neuropathy

Oral and Sublingual Ketamine (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • Phase 1 • 10 participants • Western University, Canada

Major Depression Severe

MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • Phase 2 • 30 participants • Nautilus Sanctuary

Post-Traumatic Stress Disorder, Adjustment Disorders

Effectiveness of a Sound Bowl Meditation on Caregiver Stress and Anxiety (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • 40 participants • Ohio State University

Stress, Anxiety

Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP) (opens ClinicalTrials.gov in a new tab)

Suspended • Early Phase 1 • 5 participants • University of Wisconsin, Madison

Posttraumatic Stress Disorder

Neural Effects of Intravenous N,N-dimethyltryptamine (DMT) (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • Phase 1 • 20 participants • Jon Dean

Healthy Participants Study

Pregnenolone for Cannabis Use Disorder and Depression (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • Phase 1/2 • 20 participants • University of Texas Southwestern Medical Center

Cannabis Use Disorder, Major Depressive Disorder (MDD)

The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers. (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • Phase 1 • 50 participants • Gabriella Gobbi

Healthy Participants, Placebo - Control, Psilocybin

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • Phase 1 • 120 participants • University of Wisconsin, Madison

Well-Being, Psychological, Psychedelic Experiences

The Effects of Psilocybin on Social Connectedness (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • Phase 1 • 51 participants • Yale University

Loneliness, Grief

Evaluating the Impact of SKY Breath Meditation on Stress, Well-being, and Connection in College Students (opens ClinicalTrials.gov in a new tab) Recruiting

53 participants • University of Alabama, Tuscaloosa

Stress, Anxiety, Physical Activity

Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • Phase 2 • 20 participants • Roswell Park Cancer Institute

Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm

Psilocybin Microdosing on Cognition, Mood and Quality of Life (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • Early Phase 1 • 20 participants • Yale University

Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI

Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • Phase 2/3 • 105 participants • Johns Hopkins University

Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification, Craving

Tirzepatide in the Treatment of Cannabis Use Disorder (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • Phase 3 • 15 participants • McMaster University

Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe

Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS) (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • Early Phase 1 • 10 participants • NYU Langone Health

IBS - Irritable Bowel Syndrome

Inhaled DMT for Major Depressive Disorder (opens ClinicalTrials.gov in a new tab) Recruiting

Phase 2 • 140 participants • Universidade Federal do Rio Grande do Norte

MDD, Major Depressive Disorder (MDD), Major Depression, Suicidal Ideation

Psilocybin Administration With 5-HT1a Blockade (opens ClinicalTrials.gov in a new tab) Recruiting

Early Phase 1 • 18 participants • Johns Hopkins University

Psychedelic Effects in Healthy Volunteers

Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • Phase 2 • 76 participants • University of Calgary

Post Traumatic Stress Disorder PTSD, Intimate Partner Violence (IPV)

Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • Phase 1/2 • 50 participants • Indiana University

Treatment Resistant Depression, Substance Use Disorders

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • Phase 3 • 240 participants • VA Office of Research and Development

Major Depression

Intra-Sessional Autonomic Arc Detection in Ketamine-Assisted Therapy for PTSD: A Signal Characterisation Pilot Study (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • 5 participants • Adriaan Dirk van der Wart

Post-Traumatic Stress Disorder

Research Investigating Drug Effects-2 (RiDE-2) (opens ClinicalTrials.gov in a new tab)

Not yet recruiting • Early Phase 1 • 144 participants • University of Illinois at Chicago

Cannabis Use, Substance Use Disorder (SUD), Healthy